Pharmacokinetics of Vancomycin in Adults Receiving ECMO

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

1. Vancomycin is a drug that requires precise dosing and close monitoring to avoid drug toxicity.

2. There is limited data on the change of vancomycin pharmacokinetics in patients who need extracorporeal membrane oxygenation (ECMO).

3. This control trial is to understand:

1. whether the pharmacokinetics of vancomycin is influenced by the use ECMO

2. design the most appropriate dose of vancomycin in adult patients using ECMO.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

• >18 y/o

• receiving ECMO for study group

• without ECMO for control group (sex, age, creatinine clearance match with study group)

Exclusion Criteria:

• severe burn (>30-40% BSA)

• receiving continuous renal replacement therapy or hemodialysis concurrently